DDInter1729 DDInter364
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Chlorpropamide is not recommended for the treatment of NIDDM as it increases blood pressure and the risk of retinopathy (UKPDS-33). Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites. Renal and hepatic dysfunction may increase the risk of hypoglycemia.
Sulindac {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Chlorpropamide
Sulindac {u} (Compound) causes {v} (Side Effect) Pancytopenia
Pancytopenia {u} (Side Effect) is caused by {v} (Compound) Chlorpropamide
Sulindac {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Probenecid
Probenecid {u} (Compound) resembles {v} (Compound) Chlorpropamide
Sulindac {u} (Compound) causes {v} (Side Effect) Pancytopenia
Pancytopenia {u} (Side Effect) is caused by {v} (Compound) Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Sulindac {u} (Compound) causes {v} (Side Effect) Pancytopenia
Pancytopenia {u} (Side Effect) is caused by {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Sulindac {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Sulindac {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is associated with {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Chlorpropamide
Sulindac (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Chlorpropamide (Compound)
Sulindac (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Chlorpropamide (Compound)
Sulindac (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Probenecid (Compound) and Probenecid (Compound) resembles Chlorpropamide (Compound)
Sulindac (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Glipizide (Compound) and Glipizide (Compound) resembles Chlorpropamide (Compound)
Sulindac (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Gliclazide (Compound) and Gliclazide (Compound) resembles Chlorpropamide (Compound)
Sulindac (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Tolbutamide (Compound) and Tolbutamide (Compound) resembles Chlorpropamide (Compound)
Sulindac (Compound) binds ALB (Gene) and ALB (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Chlorpropamide (Compound)